By Mariam Sunny and Michael Erman Feb 26 (Reuters) - Novavax raised its adjusted revenue forecast for 2026 on Thursday, ...

Novavax (NASDAQ:NVAX) executives told investors the company made “significant progress” in 2025 executing a strategy centered ...

Vaccine biotechnology company Novavax (NASDAQ:NVAX) reported Q4 CY2025 results beating Wall Street’s revenue expectations, ...

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 24.4% in the morning session after the company reported ...

Novavax (NasdaqGS:NVAX) reported a surprise profit for the fourth quarter, alongside revenue that was above prior expectations. The company is shifting its business model by transferring ...

Q4 2025 Earnings Call February 26, 2026 8:30 AM ESTCompany ParticipantsLuis Sanay - Vice President of Investor RelationsJohn Jacobs ...

Novavax (NVAX) stock jumps as the company beats with its Q4 2025 revenue and records full-year profitability. Read more here.

Novavax Inc. shares are down on Friday, possibly on profit-taking after the stock rallied on Thursday following the company's announcement of its fourth-quarter and full-year 2025 financial results.

Novavax Inc. NVAX shares are up on Thursday following the company’s announcement of its fourth-quarter and full-year 2025 ...

Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areas Multiple Material Transfer Agreements signed ...

Novavax Inc. (NASDAQ:NVAX) reported fourth quarter results that exceeded analyst expectations. Shares initially fell ...

Shares of Novavax soared after the company swung to an unexpected profit in the fourth quarter and exceeded its expense-reduction goals. The stock leapt 16% to $11.03 in Thursday afternoon trading, ...